A systems genomics approach to uncover the molecular properties of cancer genes.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
27 10 2020
Historique:
received: 19 02 2020
accepted: 15 10 2020
entrez: 28 10 2020
pubmed: 29 10 2020
medline: 11 3 2021
Statut: epublish

Résumé

Genes involved in cancer are under constant evolutionary pressure, potentially resulting in diverse molecular properties. In this study, we explore 23 omic features from publicly available databases to define the molecular profile of different classes of cancer genes. Cancer genes were grouped according to mutational landscape (germline and somatically mutated genes), role in cancer initiation (cancer driver genes) or cancer survival (survival genes), as well as being implicated by genome-wide association studies (GWAS genes). For each gene, we also computed feature scores based on all omic features, effectively summarizing how closely a gene resembles cancer genes of the respective class. In general, cancer genes are longer, have a lower GC content, have more isoforms with shorter exons, are expressed in more tissues and have more transcription factor binding sites than non-cancer genes. We found that germline genes more closely resemble single tissue GWAS genes while somatic genes are more similar to pleiotropic cancer GWAS genes. As a proof-of-principle, we utilized aggregated feature scores to prioritize genes in breast cancer GWAS loci and found that top ranking genes were enriched in cancer related pathways. In conclusion, we have identified multiple omic features associated with different classes of cancer genes, which can assist prioritization of genes in cancer gene discovery.

Identifiants

pubmed: 33110144
doi: 10.1038/s41598-020-75400-2
pii: 10.1038/s41598-020-75400-2
pmc: PMC7591476
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

18392

Références

Nat Protoc. 2009;4(8):1184-91
pubmed: 19617889
Nucleic Acids Res. 2019 Jul 2;47(W1):W199-W205
pubmed: 31114916
Bioinformatics. 2011 Jul 15;27(14):1986-94
pubmed: 21576180
Nat Commun. 2017 Nov 28;8(1):1826
pubmed: 29184056
Circ Res. 2018 Feb 2;122(3):433-443
pubmed: 29212778
Genome Biol. 2016 May 06;17(1):91
pubmed: 27154141
PLoS Genet. 2009 Jun;5(6):e1000534
pubmed: 19557189
Mol Cancer Ther. 2017 Nov;16(11):2598-2608
pubmed: 28835386
Sci Rep. 2018 Jul 30;8(1):11456
pubmed: 30061703
Nucleic Acids Res. 2019 Jan 8;47(D1):D941-D947
pubmed: 30371878
PLoS Comput Biol. 2015 Apr 17;11(4):e1004219
pubmed: 25885710
JAMA. 2016 Jan 5;315(1):68-76
pubmed: 26746459
Nucleic Acids Res. 2017 Jul 3;45(W1):W98-W102
pubmed: 28407145
Cancer Epidemiol Biomarkers Prev. 2017 Jan;26(1):126-135
pubmed: 27697780
Nat Genet. 2015 Feb;47(2):106-14
pubmed: 25501392
Cell. 2018 Apr 5;173(2):371-385.e18
pubmed: 29625053
Nat Rev Cancer. 2018 Nov;18(11):696-705
pubmed: 30293088
Genome Med. 2017 Mar 27;9(1):29
pubmed: 28347358
Sci Rep. 2013 Oct 02;3:2650
pubmed: 24084849
Bioinformatics. 2011 Jun 15;27(12):1739-40
pubmed: 21546393
Nucleic Acids Res. 2017 Jan 4;45(D1):D61-D67
pubmed: 27924024
Nature. 2007 Oct 18;449(7164):913-8
pubmed: 17943131
Hum Mol Genet. 2001 Apr;10(7):655-6
pubmed: 11257095
Sci Rep. 2019 Mar 19;9(1):4848
pubmed: 30890735
Nucleic Acids Res. 2019 Jul 2;47(W1):W556-W560
pubmed: 31114875
PLoS One. 2012;7(5):e37979
pubmed: 22666427
Nat Rev Genet. 2008 Jun;9(6):477-85
pubmed: 18427557
PLoS Genet. 2011 Jan 13;7(1):e1001273
pubmed: 21249183
Nat Commun. 2015 Jan 19;6:5890
pubmed: 25597830
Nucleic Acids Res. 2019 Jan 8;47(D1):D1005-D1012
pubmed: 30445434
Nature. 2014 Jan 16;505(7483):302-8
pubmed: 24429628
Cell. 2018 Apr 5;173(2):355-370.e14
pubmed: 29625052
Bioinformatics. 2011 Aug 1;27(15):2147-8
pubmed: 21685053
Nucleic Acids Res. 2019 Jan 8;47(D1):D298-D308
pubmed: 30418626
Cell. 2018 Feb 8;172(4):650-665
pubmed: 29425488
Bioinformatics. 2015 Aug 15;31(16):2601-6
pubmed: 25886982

Auteurs

Felix Grassmann (F)

Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Nobels väg 12A, 171 65, Stockholm, Sweden. felix.grassmann@ki.se.

Yudi Pawitan (Y)

Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Nobels väg 12A, 171 65, Stockholm, Sweden.

Kamila Czene (K)

Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Nobels väg 12A, 171 65, Stockholm, Sweden.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH